Education
About Us
Working with TipRanks
Follow Us
Mineralys Therapeutics, Inc. (MLYS)
NASDAQ:MLYS
MLYS Stock Chart & Stats
$31.74
-$0.99(-7.63%)
At close: 4:00 PM EST
$31.74
-$0.99(-7.63%)
Day’s Range― - ―
52-Week Range$8.24 - $47.65
Previous CloseN/A
Volume137.34K
Average Volume (3M)1.11M
Market Cap
$2.46B
Enterprise Value$1.63B
Total Cash (Recent Filing)$217.60M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.15
Next Earnings
Mar 18, 2026EPS Estimate
-0.52Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.52
Shares Outstanding79,139,950
10 Day Avg. Volume1,039,392
30 Day Avg. Volume1,113,351
Financial Highlights & Ratios
PEG Ratio-0.04
Price to Book (P/B)3.12
Price to Sales (P/S)0.00
P/FCF Ratio-3.59
Enterprise Value/Market Cap0.66
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-35.42K
Enterprise Value/Ebitda-9.06
Forecast
1Y Price Target
$50.67Price Target Upside59.63% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-2.19
Revenue Forecast (FY)$3.20M
Bulls Say, Bears Say
Bulls Say
Clinical Efficacy Across Patient GroupsPivotal trials demonstrate clinically meaningful blood pressure reductions across diverse patient subgroups regardless of age, race, sex, body mass, or background therapies, supporting broad clinical applicability.
Regulatory ProgressPositive pivotal data support an NDA submission for the oral selective aldosterone synthase inhibitor, positioning the therapy for potential regulatory approval in resistant and uncontrolled hypertension.
Safety Profile And KOL SupportLow rates of serious adverse events, treatment discontinuations, and confirmed hyperkalemia have elicited favorable assessments from cardiologist key opinion leaders, supporting likely physician adoption.
Bears Say
Comparative Trial UncertaintyKey differences in enrolled patient populations and the lack of standardized background therapy make cross-trial comparisons challenging, creating uncertainty about relative clinical advantages.
Competitive PressureProgress of a competing drug through regulatory review by a large pharmaceutical company increases competitive pressure in the same therapeutic class and could constrain potential market share.
Mineralys Therapeutics, Inc. News
MLYS FAQ
What was Mineralys Therapeutics, Inc.’s price range in the past 12 months?
Mineralys Therapeutics, Inc. lowest stock price was $8.24 and its highest was $47.65 in the past 12 months.
What is Mineralys Therapeutics, Inc.’s market cap?
Mineralys Therapeutics, Inc.’s market cap is $2.46B.
When is Mineralys Therapeutics, Inc.’s upcoming earnings report date?
Mineralys Therapeutics, Inc.’s upcoming earnings report date is Mar 18, 2026 which is in 33 days.
How were Mineralys Therapeutics, Inc.’s earnings last quarter?
Mineralys Therapeutics, Inc. released its earnings results on Nov 10, 2025. The company reported -$0.52 earnings per share for the quarter, beating the consensus estimate of -$0.613 by $0.093.
Is Mineralys Therapeutics, Inc. overvalued?
According to Wall Street analysts Mineralys Therapeutics, Inc.’s price is currently Undervalued.
Does Mineralys Therapeutics, Inc. pay dividends?
Mineralys Therapeutics, Inc. does not currently pay dividends.
What is Mineralys Therapeutics, Inc.’s EPS estimate?
Mineralys Therapeutics, Inc.’s EPS estimate is -0.52.
How many shares outstanding does Mineralys Therapeutics, Inc. have?
Mineralys Therapeutics, Inc. has 79,139,950 shares outstanding.
What happened to Mineralys Therapeutics, Inc.’s price movement after its last earnings report?
Mineralys Therapeutics, Inc. reported an EPS of -$0.52 in its last earnings report, beating expectations of -$0.613. Following the earnings report the stock price went up 5.865%.
Which hedge fund is a major shareholder of Mineralys Therapeutics, Inc.?
Currently, no hedge funds are holding shares in MLYS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Mineralys Therapeutics, Inc. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$50.67 (59.63% Upside)
$50.67 (59.63% Upside)
Blogger Sentiment
Bullish
MLYS Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 2.9M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $60.1M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.7%
Last 30 Days ▼ 10.1%
Last 30 Days ▼ 10.1%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
223.54%
12-Months-Change
Fundamentals
Return on Equity
-42.14%
Trailing 12-Months
Asset Growth
123.65%
Trailing 12-Months
Company Description
Mineralys Therapeutics, Inc.
Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and associated cardiovascular diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of patients with uncontrolled or resistant hypertension. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.
MLYS Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted several positive developments, including successful clinical trial outcomes and a strong financial position, with sufficient funds to support operations into 2028. The company is progressing well towards NDA submission. However, there were concerns regarding data imputation and increased G&A expenses. Overall, the positive aspects outweigh the challenges.View all MLYS earnings summariesMLYS Stock 12 Month Forecast
Average Price Target
$50.67
▲(59.63% Upside)
Technical Analysis
Viking Therapeutics
―
Xenon
―
Apellis Pharmaceuticals
―
NewAmsterdam Pharma Company
―
Centessa Pharmaceuticals
―
Ownership Overview
Currently, No data available
---